TY - JOUR T1 - Morphea in Childhood: An Update JO - Actas Dermo-Sifiliográficas T2 - AU - Aranegui,B. AU - Jiménez-Reyes,J. SN - 15782190 M3 - 10.1016/j.adengl.2018.03.011 DO - 10.1016/j.adengl.2018.03.011 UR - https://actasdermo.org/en-morphea-in-childhood-an-update-articulo-S157821901830088X AB - Morphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as juvenile localized scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentán, and topical imiquimod 5%. A variety of measuring tools are used to monitor response to treatment. Few prognostic studies have been conducted, but findings to date suggest that the disease tends to run a chronic or intermittent-recurrent course and frequently causes sequelae. ER -